echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > How to treat metastasis grape membrane melanoma? FDA awards tebentafusp 'breakthrough therapy title'

    How to treat metastasis grape membrane melanoma? FDA awards tebentafusp 'breakthrough therapy title'

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Grape membrane melanoma is the most common intraocular tumor, and in China, the incidence rate is second only to retinal scleoma, ranking second in intraocular tumors.
    Immunocore, a late-stage biotechnology company dedicated to developing new T-cell-specific (TCR) dual-specific immunotherapy, announced today that the U.S. Food and Drug Administration (FDA) has awarded tebentafusp (IMCgp100) a "breakthrough therapy title" (BTD) for the treatment of adult patients with non-removable or metastasis staphylocolum melanoma (mUM).
    In a randomized Phase III clinical trial (IMCgp100-202 study) in patients with previously untreated metastasis membrane melanoma, an interim analysis showed that tebentafusp significantly extended total patient survival (OS) and was superior to other immunotherapy therapies, so the trial reached its primary endpoint.
    , Tebentafusp was awarded the FDA's "fast track qualification" and "orphan drug title" as well as the "promising innovative drug title" under the UK's early drug program.
    Immunocore will work with the FDA to facilitate the launch of tebentafusp.
    if approved, Immunocore believes tebentafusp will be a new treatment for metastasis vine melanoma over 40 years.
    Bahija Jallal, Chief Executive Officer of Immunocore, said,
    We are pleased that the FDA has awarded tebentafusp a breakthrough therapy based on the survival benefits of our Phase III clinical trial announced in November 2020.
    patients urgently need approved treatments to treat this rare and aggressive melanoma."
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.